No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 974 | 1,113 | 1,379 | 1,487 | 1,610 | 1,776 | N/A | N/A |
| Operating profit | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | €m | 103 | 90 | 134 | 146 | 148 | 167 | N/A | N/A |
| EPS reported | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
SOL S.p.A., a global enterprise established in Monza, Italy, in 1927, operates as a subsidiary of Gas and Technologies World BV. The company primarily focuses on the research, manufacturing, and distribution of a diverse array of technical and medical gases, while simultaneously delivering comprehensive home healthcare solutions and associated medical equipment. Its extensive gas portfolio includes vital elements such as oxygen, nitrogen, and argon, alongside specialized gas mixtures, high-purity gases for the electronics industry, and food-grade gases. These products are supplied to various sectors including chemical, electronics, steel, metal, and food processing, as well as supporting environmental protection, scientific research, and healthcare. In the realm of home healthcare, SOL provides critical in-home therapies like oxygen, mechanical ventilation, and aerosol treatments. It also specializes in the diagnosis and management of respiratory sleep disorders, offers artificial nutrition programs, insulin pump therapy, immunotherapy, and dedicated support for pain and Parkinson's disease. Further extending its healthcare reach, the company delivers general home health and social care services, augmented by telemedicine platforms, digital health tools, and a range of healthcare aids. Beyond these core gas and home healthcare operations, SOL S.p.A. engages in a variety of complementary ventures. These encompass the design, construction, and management of biobanks; the generation and sale of hydroelectric power; and the provision of pre- and post-natal diagnostic screening. The company also develops and markets diagnostic systems and products for research and clinical applications across hospital, environmental, veterinary, and food sectors, alongside specialized bioshipping services for the secure transfer, storage, and handling of biological samples. Additional services include professional training, electromedical equipment support, hospital hygiene, environmental monitoring, and ambulance management, all facilitated by its proprietary InfoHealth SOLution web platform for operational oversight.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
SOL S.p.A., a global enterprise established in Monza, Italy, in 1927, operates as a subsidiary of Gas and Technologies World BV. The company primarily focuses on the research, manufacturing, and distribution of a diverse array of technical and medical gases, while simultaneously delivering comprehensive home healthcare solutions and associated medical equipment. Its extensive gas portfolio includes vital elements such as oxygen, nitrogen, and argon, alongside specialized gas mixtures, high-purity gases for the electronics industry, and food-grade gases. These products are supplied to various sectors including chemical, electronics, steel, metal, and food processing, as well as supporting environmental protection, scientific research, and healthcare. In the realm of home healthcare, SOL provides critical in-home therapies like oxygen, mechanical ventilation, and aerosol treatments. It also specializes in the diagnosis and management of respiratory sleep disorders, offers artificial nutrition programs, insulin pump therapy, immunotherapy, and dedicated support for pain and Parkinson's disease. Further extending its healthcare reach, the company delivers general home health and social care services, augmented by telemedicine platforms, digital health tools, and a range of healthcare aids. Beyond these core gas and home healthcare operations, SOL S.p.A. engages in a variety of complementary ventures. These encompass the design, construction, and management of biobanks; the generation and sale of hydroelectric power; and the provision of pre- and post-natal diagnostic screening. The company also develops and markets diagnostic systems and products for research and clinical applications across hospital, environmental, veterinary, and food sectors, alongside specialized bioshipping services for the secure transfer, storage, and handling of biological samples. Additional services include professional training, electromedical equipment support, hospital hygiene, environmental monitoring, and ambulance management, all facilitated by its proprietary InfoHealth SOLution web platform for operational oversight.